|
||
Original Article |
Correspondence to: Mary C. Beckerle, Department of Biology, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT 84112-5550. Tel:(801) 581-4485 Fax:(801) 581-2175 E-mail:mary.beckerle{at}hci.utah.edu.
| Abstract |
|---|
|
|
|---|
Spatially controlled actin filament assembly is critical for numerous processes, including the vectorial cell migration required for wound healing, cell- mediated immunity, and embryogenesis. One protein implicated in the regulation of actin assembly is zyxin, a protein concentrated at sites where the fast growing ends of actin filaments are enriched. To evaluate the role of zyxin in vivo, we developed a specific peptide inhibitor of zyxin function that blocks its interaction with
-actinin and displaces it from its normal subcellular location. Mislocalization of zyxin perturbs cell migration and spreading, and affects the behavior of the cell edge, a structure maintained by assembly of actin at sites proximal to the plasma membrane. These results support a role for zyxin in cell motility, and demonstrate that the correct positioning of zyxin within the cell is critical for its physiological function. Interestingly, the mislocalization of zyxin in the peptide-injected cells is accompanied by disturbances in the distribution of Ena/VASP family members, proteins that have a well-established role in promoting actin assembly. In concert with previous work, our findings suggest that zyxin promotes the spatially restricted assembly of protein complexes necessary for cell motility.
Key Words:
zyxin,
-actinin, cell motility, Ena/VASP
MANY cellular processes depend on cytoskeletal rearrangements involving actin filaments. For example, cell locomotion and membrane extension appear to be largely driven by the spatially restricted addition of actin monomers to free filament ends in the lamellipodial leading edge (![]()
![]()
![]()
![]()
![]()
![]()
One protein that has been postulated to play a role in the regulation of the actin cytoskeleton is zyxin (![]()
![]()
![]()
![]()
![]()
Among zyxin's notable structural features are an extensive proline-rich NH2-terminal domain, a nuclear export signal, and the presence of three COOH-terminal copies of the LIM motif (![]()
![]()
![]()
![]()
![]()
![]()
![]()
![]()
![]()
![]()
![]()
![]()
![]()
![]()
Zyxin also interacts with
-actinin (![]()
![]()
![]()
![]()
![]()
-actinin is in a position to contribute to membranecytoskeletal interactions by linking actin stress fibers directly to the integrin transmembrane receptors. The interaction of zyxin with
-actinin has been proposed to be important for zyxin localization and association with the cytoskeleton (![]()
In this study, we have employed a custom peptide library to map the binding site of
-actinin on zyxin, and have used this information to design a synthetic peptide inhibitor of this proteinprotein interaction. We used this peptide as a tool to further define the physiological role of zyxin and the importance of its subcellular distribution by introducing it into living cells and determining the effects on cell behavior and morphology. Introduction of the peptide inhibitor into cells causes the mislocalization of zyxin and its binding partner, Mena, a mammalian member of the Ena/VASP family. Zyxin displacement also results in retraction of the cell edge and adversely affects cell spreading and cell migration. Our results illustrate that zyxin plays an important role in cell motility. We postulate that zyxin functions in some aspect of cytoskeletal regulation and microfilament dynamics, possibly by promoting the assembly of protein complexes that stimulate actin polymerization.
| Materials and Methods |
|---|
|
|
|---|
Synthetic Peptides
Peptides were synthesized with an NH2-terminal cysteine at the University of Utah core facility or by Genosys, Inc. Lyophilized peptides were resuspended in sterile PBS, and the pH was adjusted to 7.5 if necessary. The sequence of the Zyx16-30 peptide is APAFYAPQKKFGPVV. The sequence of the scrambled peptide used as a control is VAFAKPYKQAVPGPF.
Protein Binding Studies
Binding studies with
-actinin were performed using purified
-actinin from chicken smooth muscle (![]()
-actinin binding on zyxin was determined using a custom-made peptide library (SPOTs) conjugated to a cellulose membrane (![]()
-actinin was used to probe the SPOTs membrane at a concentration of 250,000 cpm/ml.
To evaluate the ability of the soluble Zyx16-30 peptide to block the zyxin
-actinin interaction, chicken zyxin was expressed in Escherichia coli as a GST fusion protein (![]()
-actinin, or
-actinin preincubated with the Zyx16-30 peptide, or a control scrambled peptide. The strips were washed in TBS and fixed briefly in 0.5% formaldehyde, followed by washing in 2.0% glycine.
-Actinin binding to GST-zyxin was detected according to standard immunoblot procedures using an mAb against
-actinin (Sigma Chemical Co.) and HRP-conjugated antimouse IgG (Amersham Life Science) as a secondary antibody, followed by chemiluminescent detection using enhanced chemiluminescence reagents (Amersham Life Science).
To test the protein binding specificity of the Zyx16-30 peptide, the peptide was coupled to HRP via the NH2-terminal cysteine residue using EZ-LinkTM maleimide-activated HRP (Pierce Chemical Co.). Proteins present in a PtK2 cell lysate were separated by SDS-PAGE and transferred to nitrocellulose. 25 µg of coupled Zyx16-30 peptide was diluted in 5 ml TBS + 0.1% Tween 20 and was incubated with the membrane. HRP-Zyx16-30 peptide binding to protein on the blot was detected by using chemiluminescence methods. The membrane was stripped and probed with an mAb against
-actinin, followed by incubation with HRP-conjugated antimouse IgG and chemiluminescent detection.
Microscopy
Video images were collected on a Leitz Fluovert inverted scope using a Micromax CCD camera (Princeton Instruments) and analyzed using Openlab image processing software (Improvision). Cells to be processed for indirect immunofluorescence were allowed to recover at 37°C for 15 min after injection. Primary antibodies used for immunofluorescence were the following: an antizyxin polyclonal (![]()
![]()
-actinin mAbs (Sigma Chemical Co.). Secondary antibodies used were Texas red goat antirabbit IgG, FITC goat antirabbit IgG, and Texas red goat antimouse IgG (Molecular Probes).
Microinjection Experiments
Potoroo tridactylis kidney (PtK2)1 cells were plated onto glass coverslips 1836 h before microinjection. Cells were injected using an Eppendorf micromanipulator. In the experiments described here, peptides were injected at a needle concentration of 0.6 mM0.6 µM. These needle concentrations are above the threshold required for the maximal effect on cell behavior. At a needle concentration of 0.06 µM, a smaller percentage of cells displayed effects of the injected peptide. If cells were to be processed for immunofluorescence, FITC-BSA was coinjected with peptides. For injections in which the Zyx16-30 peptide was preincubated with
-actinin, the molar ratio of
-actinin to peptide was 15:1. For myosin inhibition studies, a fresh 0.5 M stock of diacetyl monoxime (ICN Laboratories) was prepared in sterile H2O and added to cell medium for a final concentration of 10 mM. Quantitative data regarding the effects of peptide injection on protein localization was obtained by visual observation of cells injected and processed for immunofluorescence. In each case, over 100 cells were injected and scored for localization of zyxin, Mena, or vinculin; analysis was performed blind and in parallel by two independent investigators.
Cell Spreading Experiments
PtK2 epithelial cells were grown to 8090% confluency. Cells were trypsinized, washed, and resuspended in sterile PBS + 10 mM MgCl at a concentration of 2.5 x 106 cells/ml. Peptide (400 µM) and a 3,000-D Texas red dextran (0.1 mg/ml) were added to the cell suspension before electroporation. An aliquot of cell suspension (0.5 ml) was placed in 2-mm gap cuvettes and electroporated using an electrocell manipulator 600 (BTX Inc.). Cells were incubated on ice for 15 min, washed, and plated onto fibronectin (Sigma Chemical Co.) -coated coverslips. 3 h after plating, cells were fixed and stained using FITC-phalloidin (Molecular Probes). After electroporation, virtually all cells examined were observed to have taken up this marker and, thus, can be assumed to have taken up peptide as well. Two independent experiments were performed; between 150 and 200 measurements were taken for each population of cells. Cell area was determined using NIH Image software, and statistical analysis was performed using Instat software (GraphPad Software, Inc.). Cellular area measurements of <100 µm2 were not included in our calculations to eliminate the possibility of including data from nonviable cells in the analysis. Data are reported as the mean area ± SEM.
Cell Migration Experiments
Normal immortalized human mammary epithelial cells (184A) were cultured in DFCI media containing 12.5 ng/ml EGF (![]()
| Results |
|---|
|
|
|---|
-Actinin Interacts with Sequences in the NH2-terminal Region of Zyxin
Zyxin is concentrated at sites proximal to the plasma membrane, including the focal adhesions and the lamellipodial leading edge, where the fast-growing ends of actin filaments are clustered. To define further the physiological role of zyxin, we sought to develop specific inhibitors of zyxin function. Our initial effort has been directed toward designing an inhibitor of the zyxin
-actinin interaction (![]()
-actinin are extensively colocalized in cells (Figure 1) and we reasoned that inhibiting this interaction might perturb zyxin's subcellular distribution.
|
We precisely mapped the site of
-actinin binding on zyxin using a custom synthesized SPOTs peptide library (![]()
-actinin was used to probe this library and was found to interact most prominently with a series of three peptides corresponding to sequences in amino acids 1333 of human zyxin (Figure 2 A). Our determination of the
-actinin binding site on zyxin using the library of zyxin-derived peptides refines the recently published domain mapping performed by deletion analysis (![]()
-actinin. Comparison of this region in human, mouse, and chicken zyxin shows that it is highly conserved (Figure 2 B). While other peptides in the library also interacted with
-actinin, their relative strength of binding was at least 50% less than that of the Zyx16-30 peptide. For this reason, we focused on the testing of the Zyx16-30 peptide as a possible inhibitor of the interaction of zyxin with
-actinin.
|
The ability of a synthetic Zyx16-30 peptide to compete with zyxin for
-actinin binding was tested. Chicken zyxin was expressed as a GST fusion protein in bacteria (Figure 3 A, lane 2). Proteins were transferred to nitrocellulose and overlaid with purified
-actinin (Figure 3 A, lanes 38).
-Actinin interacted specifically with the zyxin fusion protein (Figure 3 A, lane 4). The Zyx16-30 peptide was demonstrated to block the interaction of
-actinin with zyxin (Figure 3 A, lane 6), whereas a scrambled peptide with an identical amino acid composition did not (Figure 3 A, lane 8). This experiment demonstrated the ability of the Zyx16-30 peptide to act as an inhibitor of the zyxin
-actinin interaction.
|
To test the specificity of the peptide for binding to
-actinin, we used the Zyx16-30 peptide to probe the complex mixture of proteins present in a PtK2 cell lysate (Figure 3 B, lane 1). PtK2-derived proteins were electrophoretically resolved and transferred to nitrocellulose and were probed with HRP-conjugated Zyx16-30 peptide. The Zyx16-30 peptide interacted specifically with a protein that migrated at an apparent molecular mass of 100,000 D (Figure 3 B, lane 2). To confirm the identity of this protein as
-actinin, the membrane was stripped and probed with an mAb directed against
-actinin, which recognized the same protein profile as that bound by the zyxin-derived peptide (Figure 3 B, lane 3). These studies indicated that the Zyx16-30 peptide is likely to be a useful reagent for examining the importance of zyxin's interaction with
-actinin in vivo and for further dissection of zyxin function.
The Zyx16-30 Peptide Causes Mislocalization of Zyxin In Vivo
Once we had established the effectiveness and specificity of the Zyx16-30 peptide reagent as an inhibitor of the interaction of zyxin with
-actinin in vitro, we examined the effect of intracellular peptide on zyxin's subcellular distribution. For these studies, we used PtK2 cells, an epithelial cell line derived from rat kangaroo. This cell type has been used in several previous studies of cytoskeletal processes, including cell spreading and myosin-dependent activities (![]()
![]()
![]()
![]()
![]()
![]()
-actinin is enriched and where zyxin is also found. In addition, cells of this type are especially amenable to microinjection and the localization of cytoskeletal proteins by indirect immunofluorescence.
In PtK2 cells injected with the Zyx16-30 peptide, zyxin is substantially mislocalized; the protein is no longer concentrated in focal adhesions or at cell borders (Figure 4 A, an asterisk marks the injected cell which was identified by the presence of a fluorescent marker that was introduced with the peptide). In contrast, injection of a scrambled peptide with identical amino acid composition did not adversely affect zyxin localization (Figure 4 B). Although zyxin was substantially displaced from its normal subcellular location by the introduction of the Zyx16-30 peptide, the structural integrity of the focal adhesions is retained. Injection of the Zyx16-30 peptide did not alter the distribution of another focal adhesion constituent, vinculin (Figure 4 C), and focal adhesions could still be visualized using interference reflection contrast microscopy (data not shown). Thus, appropriate subcellular localization of zyxin does not appear to be essential for the short-term maintenance of preexisting focal adhesions. In addition, actin-rich stress fibers remain assembled in injected cells (data not shown) and
-actinin exhibits its normal periodic distribution along stress fibers (Figure 4 D). However, as will be discussed in greater detail below, actin-rich retraction fibers and dense bundles of actin filaments that run parallel to the cell edge are evident at the borders of cells that have been injected with the zyxin-derived peptide, illustrating that disturbance of the zyxin
-actinin interaction has some adverse effects on cell morphology and cytoskeletal organization (Figure 4 D).
|
Interestingly, mislocalization of zyxin is accompanied by a striking depletion of the zyxin binding partner, Mena, a member of the Ena/VASP family from its normal subcellular locations (Figure 4 E). In particular, we noted a reduction in the accumulation of Mena and VASP in focal adhesions with a concomitant increase in cytoplasmic labeling of the peptide-injected cells. In addition to the loss of Mena, mislocalization of zyxin results in a noticeable reduction in the phosphotyrosine content of the focal adhesion (Figure 4 F). Although antigen levels cannot be reliably quantified by immunocytochemical methods, the apparent reduction in phosphotyrosine content in the focal adhesions of the peptide-injected cells may reflect a loss of Ena/VASP family members from these sites since these proteins are known to be tyrosine phosphorylated (![]()
![]()
In an effort to define more quantitatively the effect of peptide injection on the protein composition of focal adhesions, cells were injected with either the Zyx16-30 peptide or the control scrambled peptide, and scored for correct localization of zyxin, Mena, and vinculin (Table 1). For each focal adhesion component considered, a minimum of 200 cells was injected and scored for protein localization by immunofluorescence. In cells injected with the scrambled peptide, less than a quarter of the cells (from 8 to 24%, depending on the protein evaluated) displayed any noticeable alteration in the normal subcellular distributions of zyxin, Mena, or vinculin. In contrast, the majority of cells injected with the Zyx16-30 peptide showed mislocalization of zyxin and Mena; in both cases ~70% of the cells displayed a clear loss of these proteins from the focal adhesions. At a minimum, these results illustrate that injection of the Zyx16-30 peptide causes the concurrent mislocalization of zyxin and Mena in ~40% of the cells examined. Only 25% of cells injected with the Zyx16-30 peptide showed mislocalized or reduced vinculin at the focal adhesion; this level is similar to what we observed for the control peptide. Our observation that vinculin remains largely concentrated in the focal adhesion after peptide injection also indicates that the loss of zyxin and Mena is unlikely to be a result of nonspecific disruption of focal adhesion structures.
|
Introduction of the Zyx16-30 Peptide into PtK2 Cells Affects the Position of the Cell Edge
If zyxin plays a role in actin dynamics, focal adhesion assembly, or cell adhesion, mislocalization of zyxin in living cells could be expected to alter cell morphology and behavior. We examined the effect of zyxin mislocalization on cell behavior at a higher resolution by microinjection of the Zyx16-30 peptide into PtK2 cells and monitoring the cellular response in real time using video microscopy. Introduction of the Zyx16-30 peptide into cells produced a rapid retraction of the cell edge (Figure 5, panel 1). A quantitative view of the results from these experiments, illustrating the dynamic behavior of the cell edge for several representative cells is shown in Figure 6. The average rate of rearward displacement for cells injected with the Zyx16-30 peptide was 2.7 microns/min during the 5-min observation period. Numerous retraction fibers were evident at the borders of these injected cells. Injection of cells with buffer solutions alone or with solutions containing BSA or
-actinin did not produce this response, indicating that it is not a result of the microinjection technique (data not shown). In addition, injection of a scrambled version of the peptide had no effect on cell morphology (Figure 5, panel 2, and Figure 6), and preincubation of the Zyx16-30 peptide with
-actinin before microinjection inhibited the effects of the bioactive peptide (Figure 5, panel 3, and Figure 6). Table 2 shows the results of several microinjection experiments in which cells were observed for several minutes after microinjection and scored for response. Nearly 90% of cells injected with the Zyx16-30 peptide exhibited retraction of the cell edge after microinjection, whereas <12% of the cells injected with control solutions displayed any evidence of retraction. The observation that the percentage of cells exhibiting edge retraction is apparently greater than the percentage of cells showing mislocalization of zyxin (compare Table 1 and Table 2) may be a reflection of the relatively stringent criteria we used to define loss of zyxin localization by immunofluorescence; some cells that we scored as lacking a disturbance in zyxin localization in response to peptide injection may indeed have sustained a disturbance in zyxin distribution sufficient to produce cell retraction, but insufficient for us to score it as mislocalized.
|
|
|
Cell shape is controlled in part by the balance between the opposing activities of actin assembly, which drives membrane protrusion, and myosin-powered retrograde movement, which causes retraction (![]()
![]()
![]()
![]()
The Zyx16-30 Peptide Inhibits Cell Spreading on Fibronectin
An attractive model for zyxin function is that of a molecular scaffold that functions to promote site-specific actin assembly. This hypothesis is consistent with zyxin's ability to promote assembly of actin-rich structures when targeted to the plasma membrane (![]()
![]()
In parallel experiments, the Zyx16-30 peptide or a scrambled peptide of identical amino acid composition was introduced into PtK2 cells in suspension via electroporation. Texas red dextran was simultaneously introduced as a marker for successful electroporation; virtually all cells examined were observed to have taken up this marker (data not shown) and, thus, can be assumed to have internalized peptide as well. After electroporation, cells were plated onto fibronectin-coated coverslips (![]()
![]()
|
Injection of the Zyx16-30 Peptide Inhibits Cell Migration
To explore further the role of zyxin in cell motility, we examined the effect of introducing the Zyx16-30 peptide into a highly migratory cell type. We used 184A cells, immortalized normal mammary epithelial cells (![]()
![]()
|
|
| Discussion |
|---|
|
|
|---|
Zyxin was discovered as a component of focal adhesions >10 yr ago, however, its physiological role has remained relatively obscure. An important insight into the possible function of zyxin within cells came with the recognition of the relationship between zyxin and the ActA protein of Listeria monocytogenes (![]()
![]()
![]()
![]()
![]()
![]()
![]()
Here, we have endeavored to test further the role of zyxin within living cells. Since the appropriate subcellular localization of a protein is often critical to its function, we reasoned that if we could develop a peptide inhibitor that interfered with the normal subcellular distribution of zyxin in living cells, the behavior of the cells might clarify the physiological role of zyxin, and/or protein complexes that depend on zyxin. The interaction of zyxin with
-actinin has been proposed to be important for zyxin's association with the cytoskeleton (![]()
In this study, we have mapped the region of zyxin that interacts with
-actinin to a region in the extreme NH2 terminus of zyxin, to amino acids 1630, and have used this information to design a peptide inhibitor of this proteinprotein interaction. In cells injected with the Zyx16-30 peptide, zyxin is substantially mislocalized. This mislocalization of zyxin is correlated with a disturbance in the distribution of the zyxin binding partner, Mena. The ability of Ena/VASP family members to interact with vinculin (![]()
![]()
The mechanism by which the Zyx16-30 peptide interferes with the normal subcellular localization of zyxin is not completely clear. A simple interpretation would be that zyxin's interaction with
-actinin is important for its subcellular distribution. Although this may indeed be the case, our preliminary results demonstrate that the LIM regions of zyxin are sufficient to target zyxin to the focal adhesions (Nix, D., S. Bockholt, and M.C. Beckerle, unpublished observations). Also, although zyxin and
-actinin are substantially colocalized, the presence of
-actinin alone cannot be sufficient to cause the recruitment of zyxin to specific cellular locations, since there are situations in which
-actinin occurs in sites that lack zyxin. Therefore, in our microinjection experiments, it appears likely that the presence of the Zyx16-30 peptide introduces some steric interference that is incompatible with the presence of full-length zyxin.
Introduction of the Zyx16-30 peptide into cells produced a clear and statistically significant decrease in the rate of cell spreading on fibronectin and in the rate of cell migration in a motile cell type. In addition, our results suggest that zyxin plays a role in maintenance of the integrity and position of the cell border. For example, in PtK2 cells, mislocalization of zyxin produces a retraction of the cell edge that is dependent on a myosin motor activity. Such effects on cell behavior would be expected if zyxin contributed to lamellipodial integrity or function. Alternatively, although some focal adhesion components, such as vinculin, still appear to be localized appropriately after microinjection of the zyxin-derived peptide, the cell behavior we observe could result from a decrease in cell adhesiveness because of partial dissolution of established focal adhesions or perturbation of nascent adhesion sites. Additional investigation will be required to evaluate whether the effects of zyxin mislocalization on cell motility results from disturbances in the function of the leading edge, substratum adhesion machineries, or both. In either case, it is intriguing to consider the possibility that a primary consequence of the mislocalization of zyxin is a reduction of localized actin polymerizing activity. Consistent with this view, it is clear that in PtK2 cells, the sites where monomeric actin is being most rapidly incorporated into existing filaments are at the focal adhesions and the edges of lamellipodia, sites where zyxin is normally detected (Figure 1; ![]()
Several lines of evidence illustrate the specificity and effectiveness of the Zyx16-30 peptide as an inhibitor of zyxin function. Biochemical tests have illustrated the ability of the zyxin-derived peptide to compete for zyxin docking sites on
-actinin, and have shown that
-actinin is the sole ligand for the peptide that is detected in cell lysates. The displacement of zyxin that we observe in living cells that have been injected with the zyxin-derived peptide suggests that this peptide can dock on
-actinin in vivo and prohibit simultaneous binding of endogenous zyxin to these sites. The fact that
-actinin retains its ability to associate with filamentous actin in cells injected with the zyxin-derived peptide, at least as evaluated by immunocytochemical methods, illustrates that the binding of the Zyx16-30 peptide to the globular head domain of
-actinin does not cause a global disturbance of
-actinin function in vivo. Thus, the zyxin-derived peptide appears to be exerting a relatively localized effect on the
-actinin globular head domain that serves as a docking site for zyxin (![]()
-actinin function, it would be necessary to perform complementary peptide competition experiments in which a peptide corresponding to the zyxin binding site on
-actinin was employed. Unfortunately, these experiments are not possible since the zyxin binding site on
-actinin does not map to a discrete collection of contiguous amino acids (data not shown). However, further support that the peptide effects on motility are specifically due to effects on zyxin comes from the use of an alternative approach to probe zyxin function in vivo. Inhibition of zyxin function by chromaphore-assisted laser inactivation also perturbs cell spreading and migration, which is consistent with the results reported here (Benson, B., F. Wang, D.G. Jay, and M.C. Berkerle, manuscript submitted for publication).
The evidence that zyxin is important for optimal cell motility is particularly interesting in light of the relationship established between zyxin and the ActA protein of L. monocytogenes (![]()
![]()
![]()
![]()
![]()
![]()
![]()
![]()
![]()
![]()
The precise mechanism by which zyxin enhances cell motility is not clarified by our studies. However, an attractive model for zyxin function is that of a molecular scaffold, which functions to facilitate the formation of a molecular complex that promotes site-specific actin assembly. This view is consistent with zyxin's ability to interact with several proteins known to be involved in cytoskeletal regulation (![]()
![]()
![]()
![]()
![]()
|
In conclusion, our efforts to probe the physiological role of zyxin demonstrate that the activity and positioning of zyxin is important in actin-dependent processes, including cell migration and cell spreading. Cell movement is a complex process that requires extensive cytoskeletal rearrangements, including spatially controlled actin assembly. This process clearly requires many participants, including nucleating factors, proteins that regulate the availability of filament ends, and proteins that facilitate filament elongation. We speculate that zyxin facilitates the recruitment of actin assembly machinery to specific subcellular domains, and that the concentration of zyxin and its partners at these sites is important for creation of a cytoplasmic zone that supports accelerated actin assembly.
| Footnotes |
|---|
The current address of B.E. Drees is Arcaris, Inc., 615 Arapeen Drive, Salt Lake City, UT 84108 ![]()
1 Abbreviation used in this paper: ptK2, Potoroo tridactylis kidney. ![]()
| Acknowledgements |
|---|
|
|
|---|
We are extremely grateful to Jurgen Wehland for his contribution of the SPOTs membrane, to Kirsten Niebuhr, Department of Cell Biology, Braunschweig, Germany, for her technical advice, to Ed King and Heather Hansen, Department of Biology, University of Utah, Salt Lake City, UT, for their assistance with confocal microscopy, and to Frank Gertler for providing anti-Mena polyclonal antisera. Purified
-actinin was supplied by Pascal Pomies (both from Department of Biology, Massachusetts Institute of Technology, Cambridge, MA). The 184A cell line was obtained from Steve Wiley's lab at the University of Utah.
This work was supported by grants from the National Institutes of Health (GM50877) and the Huntsman Cancer Institute to M.C. Beckerle. While this work was conducted, M.C. Beckerle was a recipient of a Faculty Research Award from the American Cancer Society.
Submitted: 1 October 1999
Revised: 17 November 1999
Accepted: 19 November 1999
| References |
|---|
|
|
|---|
-actinin. J. Cell Biol 116:1381-1393
-actinin, filamin, and a 130,000-dalton protein from smooth muscle. J. Biol Chem 255:1194-1199
-Actinin: immunofluorescent localization of a muscle structural protein in nonmuscle cells. Cell. 6:289-298[Medline].
-Actinin, a new structural protein from striated muscle. II. Action on actin. J. Biochem. 58:13-19
-actinin and the ß1 integrin subunit in vitro. J. Cell Biol 111:721-729
-actinin. J. Mol. Biol. 92:357-359[Medline].
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|